{"result": "(\"entity\"<|>LIPOFUNDINA<|>ORGANIZATION<|>LIPOFUNDINA is a fat emulsion used in intravenous nutrition, containing a mixture of soybean oil and medium-chain triglycerides, designed for better tolerance in newborns.)\n##\n(\"entity\"<|>SMOFLIPID<|>ORGANIZATION<|>SMOFlipid is a fat emulsion that includes a combination of soybean oil, medium-chain triglycerides, fish oil, and olive oil, used for intravenous nutrition in newborns.)\n##\n(\"entity\"<|>LIPOPLUS<|>ORGANIZATION<|>LIPOPLUS is a fat emulsion for intravenous nutrition that contains a mixture of soybean oil, medium-chain triglycerides, and fish oil, aimed at providing essential fatty acids to patients.)\n##\n(\"entity\"<|>CALCIUM<|>GEO<|>Calcium is a mineral essential for bone health, particularly important for premature newborns who may have inadequate reserves.)\n##\n(\"entity\"<|>PHOSPHORUS<|>GEO<|>Phosphorus is a mineral that plays a critical role in bone metabolism and is often supplemented in premature newborns to prevent deficiencies.)\n##\n(\"entity\"<|>MAGNESIUM<|>GEO<|>Magnesium is a mineral that is important for various bodily functions, including bone health, and may be monitored in newborns.)\n##\n(\"entity\"<|>PREMATURE NEWBORNS<|>PERSON<|>Premature newborns are infants born before 37 weeks of gestation, who are at risk for various metabolic and nutritional deficiencies.)\n##\n(\"entity\"<|>HYPERCALCEMIA<|>EVENT<|>Hypercalcemia is a condition characterized by elevated calcium levels in the blood, which can occur in premature newborns due to inadequate calcium intake.)\n##\n(\"entity\"<|>HYPOPHOSPHATEMIA<|>EVENT<|>Hypophosphatemia is a condition marked by low phosphorus levels in the blood, which can lead to altered bone deposition in premature newborns.)\n##\n(\"entity\"<|>HYPERCALCIURIA<|>EVENT<|>Hypercalciuria is a condition involving elevated calcium levels in urine, which can occur in premature newborns with inadequate calcium intake.)\n##\n(\"relationship\"<|>LIPOFUNDINA<|>SMOFLIPID<|>Both LIPOFUNDINA and SMOFlipid are fat emulsions used for intravenous nutrition in newborns, indicating a relationship in their purpose and application<|>7)\n##\n(\"relationship\"<|>LIPOFUNDINA<|>LIPOPLUS<|>LIPOFUNDINA and LIPOPLUS are both fat emulsions used in intravenous nutrition, suggesting a relationship in their function<|>7)\n##\n(\"relationship\"<|>SMOFLIPID<|>LIPOPLUS<|>SMOFlipid and LIPOPLUS are both fat emulsions for intravenous nutrition, indicating a relationship in their intended use<|>7)\n##\n(\"relationship\"<|>CALCIUM<|>PREMATURE NEWBORNS<|>Calcium is crucial for the bone health of premature newborns, establishing a direct relationship<|>8)\n##\n(\"relationship\"<|>PHOSPHORUS<|>PREMATURE NEWBORNS<|>Phosphorus is essential for the bone metabolism of premature newborns, indicating a significant relationship<|>8)\n##\n(\"relationship\"<|>MAGNESIUM<|>PREMATURE NEWBORNS<|>Magnesium is important for the overall health of premature newborns, establishing a relationship<|>6)\n##\n(\"relationship\"<|>HYPERCALCEMIA<|>PREMATURE NEWBORNS<|>Hypercalcemia can occur in premature newborns due to inadequate calcium intake, indicating a relationship<|>5)\n##\n(\"relationship\"<|>HYPOPHOSPHATEMIA<|>PREMATURE NEWBORNS<|>Hypophosphatemia can affect premature newborns due to insufficient phosphorus intake, establishing a relationship<|>5)\n##\n(\"relationship\"<|>HYPERCALCIURIA<|>PREMATURE NEWBORNS<|>Hypercalciuria can occur in premature newborns as a result of inadequate calcium intake, indicating a relationship<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: aproximadamente 4% del aporte calórico o 0,5 g/kg/día).\n\nLas manifestaciones clínicas de déficit de ácidos grasos (dermatitis, trombocitopenia, aumento de riesgo de infección y retraso de crecimiento) pueden aparecer al final de la primera semana de vida, si no se proporciona este suplemento.\n\nSe puede plantear reducir los aportes de lípidos (1g/kg/día) en situaciones especiales como infecciones graves (disminución de lipoproteinlipasa); hiperbilirrubinemia neonatal (riesgo de kernicterus); trombocitopenia <100.000/mm3; insuficiencia hepática o colestasis y enfermedades pulmonares.\n\nLos niveles de triglicéridos en suero o plasma se deben monitorizar en los pacientes que reciben lípidos, particularmente en aquellos casos con más riesgo de hiperlipidemia, como pueden ser pacientes con dosis elevadas, sepsis, catabolismo o EBPN. El objetivo es mantener cifras < 250 mg/dl, y se debe considerar la reducción de la dosis si se excede esta cifra.\n\nExisten diferentes emulsiones grasas intravenosas que contienen combinaciones variadas de aceites de soja, girasol, o pescado, a los que se añade fosfolípidos de yema de huevo y glicerina como emulsionantes. La concentración es al 20%, que es la mejor tolerada en RN. Las ventajas de las mezclas LCT/MCT (Lipofundina®) respecto a las fórmulas basadas exclusivamente en LCT ( Intralipid®) son su mayor estabilidad, la menor producción de peróxidos y de derivados proinflamatorios. Los estudios en pediatría con mezclas con omega 3 (SMOFlipid®) han demostrado su seguridad y eficacia, y existe evidencia limitada de su capacidad de revertir colestasis, y efecto beneficioso en ROP y DBP.\n---\nPauta habitual: inicio del aporte de lípidos al 20% a dosis de 1 g/kg/día y aumento progresivo de 0.5-1g/kg/día, según tolerancia, hasta el objetivo de 3 g/kg/día. Ocasionalmente se puede aumentar la dosis a 4 g/kg en niños crónicos que no logran tolerar la enteral para cubrir sus necesidades energéticas.\n\nPreparaciones disponibles en farmacia actualmente:\n\n| | g/100ml | Soja/MCT/pescado/oliva (%) | Osm/kg | Kcal/g |\n|------------|---------|---------------------------|---------|--------|\n| LIPOFUNDINA® | 20 | 50/50/0/0 | 380 | 9,6 |\n| SMOFlipid® | 20 | 30/30/15/25 | 380 | 10 |\n| LIPOPLUS® | 20 | 50/40/10 | 410 | 9,55 |\n\n## CALCIO, FÓSFORO Y MAGNESIO:\n\nLos recién nacidos prematuros están predispuestos a sufrir alteraciones en el metabolismo óseo:\n\n- Hipocalcemia: las reservas del prematuro puede ser inadecuadas y tras el parto disminuyen los niveles de Ca sérico.\n\n- El fósforo sérico (P) está frecuentemente elevado tras el parto por el bajo filtrado glomerular y la excreción disminuida de fósforo. Al pasar de un estado catabólico a uno anabólico con captación celular de fósforo, la suplementación de P será necesaria. Las nuevas pautas con aportes más elevados de proteínas desde el inicio favorecen el anabolismo precoz y aumenta el riesgo de hipofosforemia: monitorizar P desde los primeros días de vida. Sin un adecuado aporte puede producirse hipofosfatemia, que resultará en depósito óseo alterado e hipercalcemia e hipercalciuria\n\n- La retención neta depende del aporte, pero éste está limitado por la solubilidad del Ca y P en solución. La solubilidad está afectada por el pH, concentración y fuente de aminoácidos, aminoácidos (ej, la cisteína aumenta la solubilidad), y la temperatura de la solución. Para optimizar el depósito óseo ambos minerales deben administrarse juntos.\n\n- En general, la dosis de Ca elemental oscila de 25 a 75 mg/kg/día. El P puede no ser necesario en los primeros 1-2 días pero debe añadirse cuando el P sérico se estabiliza. La ratio óptima de Ca:P en la NP oscila entre 1:1.3 y 1:1.7 . Ratios más bajos se acompañan de elevación de P sérico y urinario sugiriendo inadecuada utilización del P por insuficiente ingesta de Ca. Dosis de inicio el primer día: 27 mg/kg/día.\n---\n- Aportes en fase estable de Ca y P:\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}